Redle Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 29-12-2024
- Paid Up Capital ₹ 0.21 M
as on 29-12-2024
- Company Age 16 Year, 10 Months
- Last Filing with ROC 31 Mar 2019
- Revenue %
(FY 2017)
- Profit 28.10%
(FY 2017)
- Ebitda 28.10%
(FY 2017)
- Net Worth -361.45%
(FY 2017)
- Total Assets 2305.39%
(FY 2017)
About Redle Pharmaceuticals
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.21 M, as per Ministry of Corporate Affairs (MCA) records.
Anuj Saxena, Kishan Rao, Anshul Saxena, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230MH2008PTC179741
- Company No.
179741
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Mar 2008
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Redle Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anshul Saxena  | Director | 28-Feb-2018 | Current |
| Anuj Saxena | Director | 02-Dec-2020 | Current |
| Kishan Rao | Director | 14-Oct-2013 | Current |
| Santosh Rane | Additional Director | 10-Feb-2022 | Current |
Financial Performance of Redle Pharmaceuticals.
Redle Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 28.1% increase in profit. The company's net worth observed a substantial decline by a decrease of 361.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Redle Pharmaceuticals?
In 2017, Redle Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Limelight Communications Private LimitedActive 15 years 2 monthsAnuj Saxena, Anshul Saxena and 1 more are mutual person
- Ewf Pharmaceuticals Private LimitedActive 25 years 9 months
Anuj Saxena, Anshul Saxena and 1 more are mutual person
- Apricot Capitals Private LimitedActive 16 years 10 months
Anuj Saxena, Anshul Saxena and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Redle Pharmaceuticals?
Unlock and access historical data on people associated with Redle Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Redle Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Redle Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
